Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 220 participants.

Also called NCT06858319

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 220 participants (planned count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06858319
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Canada, Malaysia, Mexico, South Korea, Spain, Taiwan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06858319. Allocation not applicable; no masking; primary purpose treatment. Start 2025-07-28 (actual); primary completion 2031-06-25 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Condition
Kidney Diseases
Condition
Kidney Diseases, Chronic
Condition
Urological Diseases
Condition
Glomerulonephritis
Condition
Glomerular Disease
Condition
Glomerulonephritis, IGA
Condition
Glomerulopathy
Condition
Immunoglobulin Disease
Intervention (Drug)
zigakibart
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06858319
Content hash
44a1621ad617307df6c171327efcc47f40aad5d5dece26413bf276a71c304e03